Shares of Innoviva, Inc. (NASDAQ:INVA) have earned an average rating of “Hold” from the six brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $12.33.

Several equities analysts have commented on INVA shares. ValuEngine upgraded shares of Innoviva from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Zacks Investment Research downgraded shares of Innoviva from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 16th. Cowen and Company set a $16.00 target price on shares of Innoviva and gave the stock a “buy” rating in a research note on Friday, July 28th. Robert W. Baird reiterated a “neutral” rating and set a $13.00 target price (up previously from $11.00) on shares of Innoviva in a research note on Thursday, July 27th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $15.00 target price on shares of Innoviva in a research note on Friday, July 28th.

ILLEGAL ACTIVITY NOTICE: “Innoviva, Inc. (INVA) Receives Average Recommendation of “Hold” from Analysts” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/31/innoviva-inc-inva-receives-average-recommendation-of-hold-from-analysts.html.

Shares of Innoviva (INVA) opened at 11.95 on Tuesday. Innoviva has a 12-month low of $8.67 and a 12-month high of $14.87. The firm has a 50 day moving average price of $13.74 and a 200 day moving average price of $12.94. The stock has a market cap of $1.31 billion, a PE ratio of 15.03 and a beta of 2.60.

Innoviva (NASDAQ:INVA) last posted its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $0.21 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.34 by ($0.13). The business had revenue of $48.64 million during the quarter, compared to analyst estimates of $57.18 million. Innoviva had a negative return on equity of 33.55% and a net margin of 52.91%. The business’s revenue was up 46.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.13 EPS. On average, equities analysts expect that Innoviva will post $1.13 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Victory Capital Management Inc. purchased a new position in Innoviva during the first quarter worth about $117,000. Cubist Systematic Strategies LLC raised its holdings in Innoviva by 37.8% during the second quarter. Cubist Systematic Strategies LLC now owns 13,005 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 3,569 shares in the last quarter. Profund Advisors LLC raised its holdings in Innoviva by 8.8% during the second quarter. Profund Advisors LLC now owns 15,220 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 1,227 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in Innoviva by 79.1% during the second quarter. State of Alaska Department of Revenue now owns 15,327 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 6,767 shares in the last quarter. Finally, TrimTabs Asset Management LLC purchased a new position in Innoviva during the second quarter worth about $206,000. 69.73% of the stock is owned by hedge funds and other institutional investors.

Innoviva Company Profile

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with MarketBeat.com's FREE daily email newsletter.